Shengdi Pharmaceutical

Shengdi Pharmaceutical (also known as Suncadia) is the primary innovative drug development and manufacturing arm of Jiangsu Hengrui Pharmaceuticals, one of China's largest pharmaceutical companies. The company operates through several key subsidiaries, including Shanghai Shengdi for research and development, Fujian Shengdi for manufacturing, and Suzhou Suncadia for biologics. Shengdi focuses on a broad range of therapeutic areas, including oncology, metabolic diseases, cardiovascular health, and ophthalmology, utilizing advanced modalities such as monoclonal antibodies, antibody-drug conjugates (ADCs), and peptides. Its portfolio features several approved products in China, such as the PD-L1 inhibitor adebrelimab and the NK1 receptor antagonist fosrolapitant, alongside a robust pipeline of late-stage candidates targeting high-prevalence conditions like obesity and various cancers. The company is a central component of Hengrui's strategy to transition from a generic-focused manufacturer to a global leader in innovative medicine.